Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Free Cash Flow (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Free Cash Flow for 7 consecutive years, with -$3.4 million as the latest value for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 77.42% year-over-year to -$3.4 million; the TTM value through Mar 2026 reached -$36.5 million, down 11.86%, while the annual FY2025 figure was -$48.0 million, 60.95% down from the prior year.
  • Free Cash Flow hit -$3.4 million in Q1 2026 for Barinthus Biotherapeutics, up from -$4.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $12.8 million in Q4 2024 and bottomed at -$18.3 million in Q3 2024.
  • Average Free Cash Flow over 5 years is -$9.0 million, with a median of -$11.9 million recorded in 2022.
  • Year-over-year, Free Cash Flow soared 394.91% in 2022 and then tumbled 301.85% in 2023.
  • Barinthus Biotherapeutics' Free Cash Flow stood at -$11.9 million in 2022, then decreased by 18.4% to -$14.1 million in 2023, then soared by 190.68% to $12.8 million in 2024, then plummeted by 133.12% to -$4.2 million in 2025, then rose by 20.65% to -$3.4 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$3.4 million, -$4.2 million, and -$10.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.